GDF15 and idiopathic pulmonary fibrosis: How GDF15 could be used alone or in combination with other biomarkers to diagnose, identify distinct disease endotypes, or measure the effectiveness of clinical interventions is unknown, but merits prospective study, perhaps as a secondary end point of an IPF clinical trial.